Preliminary Pharmacognostic, Physicochemical and Phytochemical Evaluation of Plumeria Obtuse Seed Pods

Plumeria obtuse L. (Apocynaceae) is an ornate outdoor plant. The plant was traditionally used during accidentalinjuries. However, the pharmacognosy of this plant is very poorly explored. Therefore, we have conducted this study to assess the distinctive qualities of the P. obtusa. To investigate P. obtusa seed pods’ preliminary pharmacognostic, physical-chemical, phytochemical, microscopic, and phytoconstituent potential. Initially, the shape and microscopic characteristics of plant seed pods were assessed. Physicochemical analysis was used for the standardization. Utilizing several chemical techniques, phytoconstituents were evaluated qualitatively. This was followed by quantitative estimation and analytical profiling of various phytoconstituents. The basic characteristics of the seed pod have been documented by macroscopy to be its brown color, sweet aroma, bitter flavor, coarse texture, and rough fracture. Microscopy showed the existence of vascular bundles, lignified fibers, calcium oxalate crystals and arteries. The results of the physicochemical analysis revealed no foreign organic matter, 2.8 % weight-average moisture content and a high total ash value of 14.80 compared to an acid insoluble ash value of 0.70, which indicated that there was less inorganic matter in the plant. The extractive values were 3.93, 6.03 and 10.16 % w/w for water soluble, alcohol soluble and hydro-alcoholic soluble extracts respectively. Flavonoids, glycosides, saponins, phenolic constituents, tannins and carbohydrates were found during early phytochemical analysis. Instrumental analysis has given an idea about functional groups present whereas GCMS technique helped in identification of phytoconstituents. The results of this study can be significantly used as a reference support for quality control and standardization of P. obtusa and preparation of a monograph of plant

A review on impact of pegylation on biopharmaceuticals

Covalent conjugation of polyethylene glycol (PEG) molecules to biopharmaceutical molecules is known to increase the pharmacological and medicinal characteristics of proteins and other big molecules and has been utilized effectively in 12 authorized medications. PEG reagents with straight and branched chains up to 40 kDa were utilized with a variety of PEG derivatives with varied linker chemistries. This article discusses the characteristics of PEG, the history and evolution of  PEGylation chemistry, and examples of PEGylated pharmaceuticals with a proven track record. They prefer to employ bigger PEG polymers and complicated PEG structures, although they use extremely pure and well-characterized PEG reagents. The preclinical toxicity data for PEG in PEGylated biologics that have been authorized are summarised. Microscopically detected cell vacuolization in phagocytes, which is connected to the biological function of absorption and elimination of particles and macromolecules from blood and tissues. It's possible. Side effects in toxicity tests typically relate to the active moiety of the medicine, not the PEG moiety, according to experience with commercially available PEGylated pharmaceuticals

On the brink of transformation: Clinical research

The research on drug development life cycle and bringing sole new drug to the market is a million dollar question for pharmaceutical organization. Any clinical trial consumes average of 10 to 15 years and USD 1.5-2.0 billion with uncertainty of medications for its effectiveness for human use. Hardly, one out of 10 compounds entering into the clinical trial that reaches to the market rendering a major loss to pharmaceutical or biotech company in case of trial failure. Conversely, with changing time and an increase in the number of medicines approved by regulatory authorities, the regulatory teams are increasing networks for monitoring and assembling adverse event reports from varied sources. This in turn, has increases annual exponential rise in data volumes and the companies are facing a huge challenge in processing it. To meet such challenges, organizations must sharpen their ability to introduce new wearables for clinical trials and provide advanced cognitive solution to handle large and complex datasets. This has summoned concepts like Artificial Intelligence to expedite medical science and clinical trial and pharmacovigilance attain success

A Review on Impact of Pegylation on Biopharmaceuticals

Covalent conjugation of polyethylene glycol (PEG) molecules to biopharmaceutical molecules is known to increase the pharmacological and medicinal characteristics of proteins and other big molecules and has been utilized effectively in 12 authorized medications. PEG reagents with straight and branched chains up to 40 kDa were utilized with a variety of PEG derivatives with varied linker chemistries. This article discusses the characteristics of PEG, the history and evolution of  PEGylation chemistry, and examples of PEGylated pharmaceuticals with a proven track record. They prefer to employ bigger PEG polymers and complicated PEG structures, although they use extremely pure and well-characterized PEG reagents. The preclinical toxicity data for PEG in PEGylated biologics that have been authorized are summarised. Microscopically detected cell vacuolization in phagocytes, which is connected to the biological function of absorption and elimination of particles and macromolecules from blood and tissues. It's possible. Side effects in toxicity tests typically relate to the active moiety of the medicine, not the PEG moiety, according to experience with commercially available PEGylated pharmaceuticals